Limits...
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.

Quer J, Buti M, Cubero M, Guardia J, Esteban R, Esteban JI - Infect Drug Resist (2010)

Bottom Line: To overcome the limited efficacy of SOC, more than 50 direct-acting antiviral agents (DAA) designed to target viral-encoded proteins essential in the HCV life cycle are currently under development.The rapid selection of resistant mutants associated with the quasispecies nature of HCV with high mutation and replication rates is one of the main challenges for the new HCV therapies.Predictive host and viral factors together with combination of DAAs with or without IFN and/or RBV need to be accurately evaluated to design the most effective individualized treatment strategy within the shortest time interval and with minimum side effects.

View Article: PubMed Central - PubMed

Affiliation: Liver Unit, Internal Medicine Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Barcelona, Spain;

ABSTRACT
Persistent hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma and the major indication for liver transplantation in adults. Current standard of care treatment (SOC) with pegylated-interferon-α 2 and ribavirin (RBV) has a limited efficacy and is associated with significant side effects frequently associated with poor compliance or treatment discontinuation, requiring specialized and frequent monitoring. To overcome the limited efficacy of SOC, more than 50 direct-acting antiviral agents (DAA) designed to target viral-encoded proteins essential in the HCV life cycle are currently under development. The rapid selection of resistant mutants associated with the quasispecies nature of HCV with high mutation and replication rates is one of the main challenges for the new HCV therapies. Predictive host and viral factors together with combination of DAAs with or without IFN and/or RBV need to be accurately evaluated to design the most effective individualized treatment strategy within the shortest time interval and with minimum side effects.

No MeSH data available.


Related in: MedlinePlus

Hepatitis C virus life cycle and putative targets to design specific drugs.Provided by courtesy of Dr Charles Rice and Dr Shihyun You.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108733&req=5

f1-idr-3-133: Hepatitis C virus life cycle and putative targets to design specific drugs.Provided by courtesy of Dr Charles Rice and Dr Shihyun You.

Mentions: All proteins encoded in the small HCV genome are essential for viral propagation and very attractive for therapy since inhibition of these viral proteins does not mainly affect cellular functions. Putative targets to design specific drugs include inhibitors of all steps in the HCV life cycle: viral entry, HCV RNA translation and post-translational processing, HCV replication, and viral assembly and release (Figure 1 and Table 2).


New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.

Quer J, Buti M, Cubero M, Guardia J, Esteban R, Esteban JI - Infect Drug Resist (2010)

Hepatitis C virus life cycle and putative targets to design specific drugs.Provided by courtesy of Dr Charles Rice and Dr Shihyun You.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108733&req=5

f1-idr-3-133: Hepatitis C virus life cycle and putative targets to design specific drugs.Provided by courtesy of Dr Charles Rice and Dr Shihyun You.
Mentions: All proteins encoded in the small HCV genome are essential for viral propagation and very attractive for therapy since inhibition of these viral proteins does not mainly affect cellular functions. Putative targets to design specific drugs include inhibitors of all steps in the HCV life cycle: viral entry, HCV RNA translation and post-translational processing, HCV replication, and viral assembly and release (Figure 1 and Table 2).

Bottom Line: To overcome the limited efficacy of SOC, more than 50 direct-acting antiviral agents (DAA) designed to target viral-encoded proteins essential in the HCV life cycle are currently under development.The rapid selection of resistant mutants associated with the quasispecies nature of HCV with high mutation and replication rates is one of the main challenges for the new HCV therapies.Predictive host and viral factors together with combination of DAAs with or without IFN and/or RBV need to be accurately evaluated to design the most effective individualized treatment strategy within the shortest time interval and with minimum side effects.

View Article: PubMed Central - PubMed

Affiliation: Liver Unit, Internal Medicine Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Barcelona, Spain;

ABSTRACT
Persistent hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma and the major indication for liver transplantation in adults. Current standard of care treatment (SOC) with pegylated-interferon-α 2 and ribavirin (RBV) has a limited efficacy and is associated with significant side effects frequently associated with poor compliance or treatment discontinuation, requiring specialized and frequent monitoring. To overcome the limited efficacy of SOC, more than 50 direct-acting antiviral agents (DAA) designed to target viral-encoded proteins essential in the HCV life cycle are currently under development. The rapid selection of resistant mutants associated with the quasispecies nature of HCV with high mutation and replication rates is one of the main challenges for the new HCV therapies. Predictive host and viral factors together with combination of DAAs with or without IFN and/or RBV need to be accurately evaluated to design the most effective individualized treatment strategy within the shortest time interval and with minimum side effects.

No MeSH data available.


Related in: MedlinePlus